New: Clinical trial search, funded by the National Cancer Institute
New: NCI-funded clinical trial search
Community
Tools
Company
Support
Sign in
Join for Free
Join for Free
Community
Would you consider adding a CDK 4/6 inhibitor to Elacestrant after progression on AI with presence of +ESR1 mutation?
Good Question
1
Save
Request Answers
Share
Add Answer
